CureVac NV Q4 2024 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Alec Stranahan - Bank of America - Analyst : Hey guys, thanks for taking our questions and congrats on the progress to close '24. Two questions from us. Maybe first -- actually, both are on the squamous program. The use of the antigens outside of the exome is pretty unique to this program. What would you say maybe the early signs you point folks to in the first-in-human clinical readout as evidence that including these antigens is maybe having a preferential effect on activity? And is it safe to say that the first patient dose in the second half of this year would set you up to maybe a mid or second half '26 readout from the Phase 1. Didn't see this on your catalyst slide in your prepared remarks. Thank you.

Question: Alec Stranahan - Bank of America - Analyst : Yeah. No, just more in terms of data readout time. Obviously, pace of enrollment is probably the biggest swing factor here, but I just didn't see a data catalyst on, I think, of a slide 14, if you prepared that?

Question: Alec Stranahan - Bank of America - Analyst : Got it. Thank you.

Question: Roger Song - Jefferies - Analyst : Thanks for that day. And then taking on question, a couple of questions maybe the first one related to GBM given the Part B data can be second half and then you will have -- you will make go-forward decisions. So just curious what is the criteria to make that decision? And then on the squamous small cell lung cancer, this multi-complex antigen selection is very interesting. Just curious, given you say 95% of the patient, they have a one-plus antigen, 50% have four-plus. Just curious in your preclinical model, do you see the difference when you -- the model only have for one versus four plus? You see the difference on the activity anti-tumor activity. The last part of the question is regarding your cash runway guidance into 2028. Just -- can you give us some color around how much operation is included in this cash runway guidance given you have a couple of ongoing pipeline and then new pipeline coming like GBM, squamous lung, and UTI? And then this cash will incur the Phase 1, Phase 2 implant? Thank you.

Question: Roger Song - Jefferies - Analyst : Thank you.

Question: Eliana Merle - UBS - Analyst : Great. Thank you.

Question: Roy Buchanan - Citizens JMP Securities LLC - Analyst : Thanks for taking the questions. I had a few on the European patent proceedings. I guess can you give us a sense of the timelines for the infringement hearing and possibly that assuming that's positive, the damage proceedings for the 668 and 755, that was just upheld and solid. And then does Pfizer and BioNTech, do they have a chance to appeal the validity decision for 668? And then can you give a little bit of more detail on the subject to amendments comment in the slide 14, I think, or 6? Thanks.

Question: Roy Buchanan - Citizens JMP Securities LLC - Analyst : Yeah, I'm just curious to subject to amendment comment on the --

Question: Roy Buchanan - Citizens JMP Securities LLC - Analyst : Okay. Great. And then maybe just throwing one on the Genmab collaboration that was terminated. Can you just give us the crux of why that was terminated and what stage it got to? Thanks.

Question: Roy Buchanan - Citizens JMP Securities LLC - Analyst : Okay. Thank you. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. APRIL 10, 2025 / 1:00PM, CVAC.OQ - Q4 2024 CureVac NV Earnings Call

Question: Jonathan Miller - Evercore ISI - Analyst : Hi guys, thanks for taking the question and congrats on the recent progress. Maybe i'll start with one on the non-small cell program. Obviously, you like others are trying to develop this primarily in early-stage setting. But of course, the Phase 1 is in later-stage patients and metastatic patients. So I'd just love to get a sense for what you're hoping to see in that Phase 1 data that would move you to early-stage setting? Do you need to see efficacy signs of early efficacy in metastatic setting beyond maybe immune engagement or T cell induction for instance? Do you need to see increases in ORR, increases in PFS to drive early stage or would safety and immune engagement be sufficient to make that decision? And then secondly, maybe on the IP case. But I'll let you answer cancer first, please.

Question: Jonathan Miller - Evercore ISI - Analyst : Yeah, absolutely. I guess one more then on that. On the novel X-exome antigens, I'd be really curious to see more of that preclinical data, more that antigen development data. Do you have plans in the near term to discuss that antigen selection process more to get deeper into the contribution of those X-exome novel antigens to immune engagement and efficacy?

Question: Jonathan Miller - Evercore ISI - Analyst : Okay, makes sense. On the IP front, the poly-A patent that was just held up in the EPO, is this the same set of IP that was struck down in the UK court last year, I believe it was in the last year? And if so, can you discuss maybe some of the differences between those two cases and whether we should be reading through from some prior that they brought into the potential for the patents in the US court? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. APRIL 10, 2025 / 1:00PM, CVAC.OQ - Q4 2024 CureVac NV Earnings Call

Question: Alec Stranahan - Bank of America - Analyst : All right. Fair enough. I look forward to that.

Question: Kiara Manitroni - Kempen - Analyst : Hello team. Thanks a lot for taking my question. This is Kiara. I am on for Suzanne van Voorthuizen. Congratulations with the progress. I was wondering on the glioblastoma program. How should we think about the translation of immunogenicity data to tumor responses? And then I was curious to know for the next indication for the shared antigen vaccine, how do you usually go about selecting indication besides, let's say, having a common expression of the antigen on these tumors?

Question: Kiara Manitroni - Kempen - Analyst : Yes, very clear. Thank you.

Question: Kiara Manitroni - Kempen - Analyst : Yes, absolutely. Thank you.